Cumberland Pharmaceuticals Inc.
CPIX
$2.28
$0.125.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.95M | 40.74M | 39.75M | 36.54M | 34.75M |
| Total Other Revenue | 1.33M | 1.33M | 1.33M | 1.33M | 2.04M |
| Total Revenue | 41.28M | 42.07M | 41.08M | 37.87M | 36.79M |
| Cost of Revenue | 6.40M | 6.74M | 6.44M | 6.59M | 6.14M |
| Gross Profit | 34.88M | 35.34M | 34.65M | 31.28M | 30.65M |
| SG&A Expenses | 28.35M | 28.42M | 28.32M | 28.15M | 28.80M |
| Depreciation & Amortization | 4.48M | 4.55M | 4.64M | 4.75M | 4.48M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.54M | 45.06M | 44.35M | 44.30M | 44.21M |
| Operating Income | -3.26M | -2.99M | -3.27M | -6.43M | -7.43M |
| Income Before Tax | -3.38M | -2.96M | -3.32M | -6.47M | -10.78M |
| Income Tax Expenses | -39.90K | -34.20K | -28.50K | -22.80K | 59.20K |
| Earnings from Continuing Operations | -3.34 | -2.93 | -3.29 | -6.44 | -10.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 9.50K | -5.90K | 16.60K | -36.10K | -26.30K |
| Net Income | -3.33M | -2.93M | -3.28M | -6.48M | -10.87M |
| EBIT | -3.26M | -2.99M | -3.27M | -6.43M | -7.43M |
| EBITDA | 1.34M | 1.69M | 1.51M | -1.53M | -2.79M |
| EPS Basic | -0.23 | -0.21 | -0.24 | -0.46 | -0.77 |
| Normalized Basic EPS | -0.15 | -0.14 | -0.16 | -0.30 | -0.34 |
| EPS Diluted | -0.24 | -0.22 | -0.25 | -0.47 | -0.78 |
| Normalized Diluted EPS | -0.15 | -0.15 | -0.16 | -0.30 | -0.34 |
| Average Basic Shares Outstanding | 58.83M | 57.93M | 57.08M | 56.24M | 56.43M |
| Average Diluted Shares Outstanding | 59.15M | 58.24M | 57.40M | 56.24M | 56.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |